IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IPA

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/28	07 : 16	Business Wire	ImmunoPrecise Antibodies (IPA) annonce la réalisation d'un placement d'actions sur le marché et la conversion complète de la débenture de Yorkville	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/28	00 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/27	22 : 01	Business Wire	ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/25	03 : 58	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/23	04 : 19	Business Wire	IPA (ImmunoPrecise Antibodies), pionnier des thérapies GLP-1 conçues par l'IA : Un nouveau chapitre potentiel en matière de traitement du diabète	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/23	00 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/22	21 : 02	Business Wire	IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/18	11 : 25	Business Wire	ImmunoPrecise Antibodies redéfinit sa stratégie de pipeline en faisant appel à l'IA et à l'innovation basée sur les principes premiers pour la découverte de médicaments	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/18	01 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/17	22 : 01	Business Wire	ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/04	00 : 20	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/01	21 : 44	Business Wire	L'IPA annonce la démission de sa directrice financière	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2025/01/01	09 : 56	Business Wire	IPA Announces Resignation of Chief Financial Officer	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/24	02 : 02	Business Wire	ImmunoPrecise Antibodies (IPA) démontre une solide confiance du marché avec des achats d'actions par des membres de la direction	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/23	23 : 03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/23	22 : 30	Business Wire	ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/20	02 : 56	Business Wire	Présentation de l'IPA à la Microcap Conference 2025	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/19	22 : 00	Business Wire	IPA to Present at The Microcap Conference 2025	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/11	20 : 34	Business Wire	ImmunoPrecise Antibodies (IPA) publie ses résultats financiers et les faits saillants de ses activités du deuxième trimestre de l’exercice 2025	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/10	22 : 37	Edgar (US Regulatory)	Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/10	22 : 36	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/10	22 : 33	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/10	22 : 30	Business Wire	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/05	20 : 23	Business Wire	L'IPA participera à la prochaine conférence de découverte en tête-à-tête d'investisseurs organisée par The Benchmark Company	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/04	22 : 00	Business Wire	IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/04	13 : 08	Business Wire	L'IPA publiera ses résultats financiers et les faits importants de son activité récente pour le deuxième trimestre de l'exercice 2025 le 10 décembre 2024	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/03	22 : 33	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/12/03	22 : 30	Business Wire	IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/11/15	05 : 13	Business Wire	Une percée commerciale de 20 milliards de dollars : l'IPA est pionnière dans le développement d'anticorps à fort impact pour les thérapies anticancéreuses ADC de nouvelle génération	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/11/13	23 : 17	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd